| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |